Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 5/20 | 0.44 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12451260 | 0.98 | DGKA (0.47) | DGKATSHRHPGDL3MBTL1FAAH | |
| SCHEMBL4570246 | 0.98 | DGKA (0.47) | DGKATSHRHPGDL3MBTL1FAAH | |
| SCHEMBL13849633 | 0.98 | DGKA (0.47) | DGKATSHRHPGDL3MBTL1FAAH | |
| SCHEMBL14370086 | 0.96 | DGKA (0.45) | DGKATSHRHPGDL3MBTL1FAAH | |
| SCHEMBL10308812 | 0.95 | NAAA (0.44) | DGKATSHRHPGDL3MBTL1FAAH | |
| SCHEMBL13324820 | 0.95 | DGKA (0.44) | DGKATSHRHPGDL3MBTL1FAAH | |
| SCHEMBL13324790 | 0.95 | DGKA (0.44) | DGKATSHRHPGDL3MBTL1FAAH | |
| SCHEMBL13324822 | 0.94 | DGKA (0.43) | DGKATSHRHPGDL3MBTL1FAAH | |
| SCHEMBL13324815 | 0.94 | DGKA (0.43) | DGKATSHRHPGDL3MBTL1FAAH | |
| SCHEMBL14408858 | 0.94 | DGKA (0.43) | DGKATSHRHPGDL3MBTL1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8702223-B2 | Infrared-absorbing radiation-curable inks | XEROX CORPORATION (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120162333-A1 | Infrared-Absorbing Radiation-Curable Inks | XEROX CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
| US-7714040-B2 | Phase change inks containing curable amide gellant compounds | XEROX CORPORATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-7276614-B2 | Curable amide gellant compounds | XEROX CORPORATION (US) | 2007-10-02 | — | — | US | disclosed |
| US-7271284-B2 | Process for making curable amide gellant compounds | XEROX CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-7259275-B2 | Method for preparing curable amide gellant compounds | XEROX CORPORATION (US) | 2007-08-21 | — | — | US | disclosed |
| US-20070123606-A1 | Phase change inks containing curable amide gellant compounds | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20070123724-A1 | Method for preparing curable amide gellant compounds | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20070123663-A1 | Process for making curable amide gellant compounds | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20070123722-A1 | Ester-terminated oligoamides and polyamides having terminal ethylenic double bonds; gelling agents for phase change ink jet inks with improved ultraviolet curability and solubility | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123724-A1 | Method for preparing curable amide gellant compounds | ODC1, INO80C, AOC1 | DGKA 1213/4885TSHR 2143/4885HPGD 611/4885 |
| US-20070123722-A1 | Ester-terminated oligoamides and polyamides having terminal ethylenic double bonds; gelling agents for phase change ink jet inks with improved ultraviolet curability and solubility | CCNA2, ELL, CCNA1 | DGKA 3286/4885TSHR 3048/4885HPGD 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.